CRISPR/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients

CRISPR/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients

Background & Aims The WHO declared to eliminate hepatitis B virus (HBV) by 2030. However, an increasing number of patients are presenting with low-level viremia (LLV) with the widespread use of antiviral medications. The diagnostic efficiency and coverage area of HBV infection are low. Hence, th...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuan Tian, Zihao Fan, Ling Xu, Yaling Cao, Sisi Chen, Zhenzhen Pan, Yao Gao, Hao Li, Sujun Zheng, Yingmin Ma, Zhongping Duan, Xiangying Zhang, Feng Ren
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Emerging Microbes and Infections
Subjects:
HBV DNA
CRISPR/Cas13a
Low-level viremia
Recombinase-aided amplification (RAA)
Detection
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2023.2177088
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items